TP53 and non-small cell lung carcinoma: Genomic analysis of the 185 NSCLC patients revealed concurrent KRAS and TP53 hotspot mutations (KRAS+/TP53+) in 19 patients (10%), TP53 hotspot mutations only (KRAS-/TP53+) in 67 patients (36%), KRAS hotspot mutations only (KRAS+/TP53-) in 33 patients (18%), and no hotspot mutations (KRAS-/TP53-) in 66 patients (36%).